Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trace Lithium for Prevention of Cognitive Decline in Mood Disorders
NCT06662526Phase 4Not yet recruiting
- Sponsor
- Universidad de Chile
- Start
- Nov 2024
- Primary completion
- Nov 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Trace lithium dose with Placebo (2 arms). Primary endpoint: Incidence of Mild Cognitive Impairment (MCI) or worsening of preexisting MCI at 5 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
lithium
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06662526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662526.